4 potential pulmonary fibrosis therapies to watch

IPF image from Wikipedia

The drug development landscape in idiopathic pulmonary fibrosis is changing rapidly. “There are probably 30 or 40 different compounds in development,” said Dr. Toby Maher, a presenter at the Pulmonary Fibrosis Foundation (PFF) Summit held last month. Of those, a handful have reached Phase 2 and Phase 3 clinical trials. Here, we highlight a handful of pulmonary fibrosis therapy candidates.

1. Pamrevlumab

One of the pathways drug developers have explored to treat IPF involves connective tissue growth factor (CTGF). The protein signals to cells to stimulate the development of fibrotic tissue In IPF. “We know that there’s an excess of CTGF,” Maher said. “And we know that that can be blocked using antibodies.”

This observation led to the development of a monoclonal antibody first called FG3019 and later rechristened as pamrevlumab.

Developed by FibroGen (NSDQ:FGEN), Pamrevlu…

Read more
  • 0